 View printer-friendly version |
| << Back |
| ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2009 Financial Results |
| CAMBRIDGE, Mass., Mar 10, 2010 (BUSINESS WIRE) -- ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
hold a live webcast of its quarterly conference call at 8:30 a.m. (ET)
on Tuesday, March 16, 2010. Harvey J. Berger, M.D., chairman and chief
executive officer, will host the call. Senior management will discuss
the Company's financial results as of December 31, 2009, key corporate
objectives and additional corporate activities. The Company will
announce the highlights of these topics in a press release to be issued
before the market opens on March 16, 2010 prior to the conference call.
The live webcast can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. The call can be accessed by dialing 866-383-8003 (domestic) or 617-597-5330 (international) five minutes prior to the start time and providing the pass code 51909292. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks. About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD's second internally discovered product candidate, AP24534, is an investigational pan-BCR-ABL inhibitor completing Phase 1 clinical development in patients with hematological cancers, notably chronic myeloid leukemia. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-kB cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit http://www.ariad.com. SOURCE: ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals |
News release
©2009 ARIAD Pharmaceuticals, Inc.